Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a global biopharmaceutical company listed on Euronext Amsterdam and Nasdaq that focuses on rare, debilitating, and life‑threatening diseases. Its news flow reflects both commercial performance and clinical development across a portfolio that includes the recombinant C1 esterase inhibitor RUCONEST® for acute hereditary angioedema (HAE) attacks and Joenja® (leniolisib), an oral PI3Kδ inhibitor for activated phosphoinositide 3‑kinase delta syndrome (APDS).
On this page, readers can follow company announcements on quarterly and annual financial results, preliminary revenue updates, and guidance changes, where Pharming explains how demand for RUCONEST® and Joenja® contributes to its revenue mix. The company also issues news about participation in healthcare and investor conferences, such as rare disease summits and global healthcare meetings, where management discusses markets like HAE and APDS.
Pharming’s communications highlight regulatory and clinical milestones, including U.S. FDA Priority Review of a supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years, Phase II proof‑of‑concept trials in primary immunodeficiencies with immune dysregulation, and pivotal studies such as the FALCON trial of KL1333 in mitochondrial DNA‑driven mitochondrial disease. Scientific updates around major congresses feature new clinical, economic, and real‑world data on RUCONEST® and Joenja®.
Investors and followers of PHARM can use this news feed to track developments in Pharming’s rare disease portfolio, including commercial updates, pipeline progress, organizational changes, and index movements such as its promotion to the Euronext AMX® (MidCap) index.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The virtual event will feature a presentation by CEO Sijmen de Vries and CMO Anurag Relan on Wednesday, February 12 at 08:40 ET/14:40 CET.
Investors can access both the live webcast and replay of the presentation through the 'Upcoming Events' and 'News' sections of Pharming's website. Those interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their Oppenheimer representative.
Pharming Technologies B.V. has successfully completed its recommended cash offer to Abliva AB shareholders, achieving 87.7% acceptance of total shares at SEK 0.45 per share. Although the original offer was conditional upon reaching 90% ownership, Pharming has waived this condition and declared the offer unconditional.
Settlement for shares tendered up to February 7, 2025, is expected around February 14, 2025. The acceptance period has been extended to February 20, 2025, at 15:00 CET, with settlement for this extended period expected around February 27, 2025.
Additionally, Pharming has acquired all outstanding warrants from holders at prices ranging between SEK 0.03-0.054 per warrant. If Pharming reaches 90% ownership, it plans to initiate a compulsory acquisition of remaining shares and pursue delisting from Nasdaq Stockholm.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) has announced an Extraordinary General Meeting (EGM) scheduled for March 4, 2025, at 14:00 CET. The primary purpose is to appoint Fabrice Chouraqui as Executive Director and Chief Executive Officer for a four-year term, succeeding Sijmen de Vries. The agenda includes approving components of Chouraqui's remuneration package.
The meeting will be held physically at the Corpus Congress Centre in Oegstgeest, Netherlands, with shareholders having the option to attend in person or follow via live webcast. All relevant documents, including the Notice to Convene, Explanatory Notes, and voting information, are available on the company's website under the Investors/Shareholder Meetings section.
Pharming Group has nominated Fabrice Chouraqui as its new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. The appointment will be for a four-year term, subject to shareholder approval at an upcoming Extraordinary General Meeting. De Vries will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition.
Chouraqui brings extensive global pharmaceutical and biotechnology experience. He previously served as CEO-Partner at Flagship Pioneering and CEO of Cellarity, Inc., where he raised over $250M. His prior roles include President of Novartis Pharmaceuticals USA (2016-2019) and various leadership positions at Bristol-Myers Squibb. He holds an MBA from INSEAD and a Doctorate in Pharmacy from the University of Paris V.
Pharming Group N.V. has announced a public cash offer to acquire all shares of Abliva AB for SEK 0.45 per share, valuing the transaction at approximately US$66.1 million. Abliva's lead product, KL1333, is currently in a pivotal clinical trial for treating primary mitochondrial disease (PMD) with mitochondrial DNA mutations, targeting over 30,000 potential patients in the U.S., EU4, and UK.
The acquisition will be funded through existing cash, with Abliva's Board of Directors unanimously recommending shareholders accept the offer. The company has secured acceptance undertakings from the three largest shareholders, representing 49.82% of outstanding shares. The acceptance period is expected to run from January 16, 2025, to February 7, 2025.
Pharming Group announces positive topline results from its Phase III clinical trial of leniolisib in children aged 4-11 years with APDS (activated phosphoinositide 3-kinase delta syndrome), a rare primary immunodeficiency. The trial enrolled 21 children across the US, Europe, and Japan, evaluating the oral PI3Kδ inhibitor's safety, tolerability, and efficacy.
The study met its primary endpoints, showing improvement in lymphoproliferation and immunophenotype correction across all dose levels, consistent with previous results in adolescent and adult patients. All patients completed the 12-week treatment period with only mild to moderate adverse events reported. Pharming plans to include this data in global regulatory filings for pediatric approval starting in 2025.
Pharming Group has announced its participation in the Jefferies London Healthcare Conference 2024, scheduled for November 19-21 in London, U.K. CEO Sijmen de Vries will deliver a presentation on Wednesday, November 20 at 08:00 GMT/09:00 CET. The presentation will be accessible via live webcast, with a replay available in the 'Upcoming Events' and 'News' sections of Pharming's website. Interested parties can arrange one-to-one meetings with Pharming's management team by contacting their Investor Relations team or Jefferies representative.
Pharming Group reported strong Q3 2024 financial results with total revenues increasing 12% to US$74.8 million. RUCONEST® revenue grew 6% to US$63.6 million, while Joenja® revenue jumped 72% to US$11.2 million. First nine months revenues rose 25% to US$204.5 million. Operating profit increased to US$4.1 million from US$1.9 million in Q3 2023. The company maintains its 2024 revenue guidance of US$280-295 million. CEO Sijmen de Vries announced he will not seek reappointment at the May 2025 AGM. The company also announced the start of a Phase II trial evaluating leniolisib in primary immunodeficiencies.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced that it will release its preliminary (unaudited) third quarter 2024 financial results on Thursday, October 24, 2024. The results will cover the period ended September 30. The company will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on the same day.
To participate in the conference call, interested parties must register in advance using the provided link. Upon registration, dial-in information and a unique PIN will be provided for call access. The company will only take questions from dial-in attendees. Additionally, a live webcast of the presentation will be available, with a separate registration link provided for those who wish to watch online.
Pharming Group (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) has initiated a Phase II clinical trial to evaluate leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes. The trial will include patients with ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency, and PTEN deficiency, among others. These PIDs have a prevalence of approximately seven patients per million, compared to one to two per million for APDS.
The study, conducted at the National Institutes of Health (NIH), is a single arm, open-label, dose range-finding study with approximately 12 patients. It aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and explore clinical efficacy of leniolisib in the targeted PID population. This trial represents Pharming's second PID clinical program for leniolisib, expanding beyond its current approved use for APDS in adults and pediatric patients 12 years and older.
